Discontinued ProductUnfortunately Sulindac (Cat. No. 1707) has been withdrawn from sale for commercial reasons.
Prodrug. Metabolizes to sulindac sulfide, a cyclooxgenase inhibitor that represses ras signaling, and sulindac sulfone, an antitumor agent, following oral administration in vivo. Widely used anti-inflammatory agent.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Preparing Stock Solutions
The following data is based on the product molecular weight 356.41. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.81 mL||14.03 mL||28.06 mL|
|5 mM||0.56 mL||2.81 mL||5.61 mL|
|10 mM||0.28 mL||1.4 mL||2.81 mL|
|50 mM||0.06 mL||0.28 mL||0.56 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Haanen (2001) Sulindac and its derivatives: a novel class of anticancer agents. Curr.Opin.Investig.Drugs 2 677 PMID: 11569947
Shen and Winter (1977) Chemical and biological studies on indomethacin, sulindac and their analogs. Adv.Drug Res. 12 90 PMID: 343530
Taylor et al (2000) Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res. 60 6607 PMID: 11118042
View Related Products by Product Action
Keywords: Sulindac, supplier, Cyclooxygenase, inhibitors, inhibits, COX, Oxygenases, Oxidases, Cyclooxygenase, Cyclooxygenase, Tocris Bioscience
1 Citation for Sulindac
Citations are publications that use Tocris products. Selected citations for Sulindac include:
Hagen et al (2015) Comparative Multi-Donor Study of IFNγ Secretion and Expression by Human PBMCs Using ELISPOT Side-by-Side with ELISA and Flow Cytometry Assays. Cells 4 84 PMID: 25679284
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.